Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06461182
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-05-23
Brief Title:
Ga-68-CXCR4 PETCT in Indolent B-cell Lymphoma
Sponsor:
Koo Foundation Sun Yat-Sen Cancer Center
Organization:
Koo Foundation Sun Yat-Sen Cancer Center
Study Overview
Official Title:
Ga-68-CXCR4 PETCT in Detecting Evaluating Response to Treatment and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PentixaFor
Brief Summary:
This study explores the efficacy of Ga-68-PentixaFor PETCT in detecting assessing treatment response and monitoring the risk of aggressiveness in indolent B-cell lymphoma The background introduces CXCR4 and discusses its role in cancer research Currently FDG-PET is the primary imaging tool for lymphoma staging but it lacks diagnostic accuracy for low-grade lymphomas Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas suggesting its potential as a superior imaging modality for low-grade lymphomas
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None